CCR10
趋化因子受体
CCR1
CCL21型
嵌合抗原受体
癌症研究
趋化因子受体CCR5
趋化因子受体
趋化因子
趋化因子受体
CXCL2型
C-C趋化因子受体6型
CCL18型
CCL7型
免疫学
生物
T细胞
免疫系统
作者
Pengfei Zhang,Chuang Wang,Le Zhang,Qiu Li
出处
期刊:Immunotherapy
[Future Medicine]
日期:2022-03-02
卷期号:14 (6): 459-473
被引量:4
标识
DOI:10.2217/imt-2021-0228
摘要
Currently, the antitumor efficacy of chimeric antigen receptor T cells in solid tumors is modest. Both chemokines and their receptors play a key role in the proliferation of cancer cells, tumor angiogenesis, organ-selective metastasis and migration of immune cells to solid tumors. Unfortunately, frequent chemokine/chemokine receptor ‘mismatch’ between effector cells and the tumor microenvironment results in inefficient T-cell infiltration and antitumor efficacy. Thus, reversing the ‘mismatch’ of chemokines and chemokine receptors appears to be a promising method for promoting T-cell infiltration into the tumor and enhancing their antitumor efficacy. In this review, we discuss functions of the chemokine/chemokine receptor axis in cancer immunity and the current understanding, challenges and prospects for improving the effect of chimeric antigen receptor T cells by reversing the mismatch between chemokines and chemokine receptors.
科研通智能强力驱动
Strongly Powered by AbleSci AI